OBJECTIVES: This study sought to test the hypothesis that pressure stress of the adenylyl cyclase 6-deleted (AC6-KO) heart would result in excessive hypertrophy, early dilation and dysfunction, and increased fibrosis. BACKGROUND: Cardiac-directed AC6 expression attenuates left ventricular (LV) hypertrophy and dysfunction in cardiomyopathy. METHODS: AC6-KO and control (CON) mice underwent transverse aortic constriction (TAC) to induce pressure overload. Measures of LV hypertrophy, function, and fibrosis were obtained 3 weeks after TAC, and LV samples were assessed for alterations in expression of FHL1 and periostin. RESULTS: Three weeks after TAC, female AC6-KO mice had preserved left ventricular (LV) ejection fraction (CON: 22+/-2%; AC6-KO: 52+/-4%; p<0.001) and reduced LV end-diastolic dimension (CON: 4.6+/-0.1 mm; AC6-KO: 3.6+/-0.1 mm; p<0.001). Reduced LV/tibial length ratio (CON: 10.4+/-1.5 mg/mm; AC6-KO: 7.5+/-2.3 mg/mm; p<0.001) and reduced LV expression of atrial natriuretic factor (p<0.05), alpha-skeletal muscle actin (p<0.05), and beta-myosin heavy chain (p<0.05) were observed in AC6-KO mice. In addition, AC6 deletion was associated with less LV fibrosis (p<0.01) and reduced collagen types I (p<0.05) and III (p<0.05) expression 3 weeks after TAC. LV protein expression of FHL1 (p<0.02) and periostin (p=0.04) were reduced after TAC in AC6-KO mice. The roles of AC6 deletion in cardiac myocytes and fibroblasts were examined in vitro using pharmacological hypertrophy and AC6 knockdown (small interfering ribonucleic acid), which recapitulated in vivo findings. CONCLUSIONS: The deleterious effects of LV pressure overload were reduced in female mice with AC6 deletion. Reductions in FHL1 and periostin expression, direct consequences of reduced AC6 in cardiac myocytes and fibroblasts, appear to be of mechanistic importance for these unanticipated beneficial effects. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
OBJECTIVES: This study sought to test the hypothesis that pressure stress of the adenylyl cyclase 6-deleted (AC6-KO) heart would result in excessive hypertrophy, early dilation and dysfunction, and increased fibrosis. BACKGROUND: Cardiac-directed AC6 expression attenuates left ventricular (LV) hypertrophy and dysfunction in cardiomyopathy. METHODS:AC6-KO and control (CON) mice underwent transverse aortic constriction (TAC) to induce pressure overload. Measures of LV hypertrophy, function, and fibrosis were obtained 3 weeks after TAC, and LV samples were assessed for alterations in expression of FHL1 and periostin. RESULTS: Three weeks after TAC, female AC6-KO mice had preserved left ventricular (LV) ejection fraction (CON: 22+/-2%; AC6-KO: 52+/-4%; p<0.001) and reduced LV end-diastolic dimension (CON: 4.6+/-0.1 mm; AC6-KO: 3.6+/-0.1 mm; p<0.001). Reduced LV/tibial length ratio (CON: 10.4+/-1.5 mg/mm; AC6-KO: 7.5+/-2.3 mg/mm; p<0.001) and reduced LV expression of atrial natriuretic factor (p<0.05), alpha-skeletal muscle actin (p<0.05), and beta-myosin heavy chain (p<0.05) were observed in AC6-KO mice. In addition, AC6 deletion was associated with less LV fibrosis (p<0.01) and reduced collagen types I (p<0.05) and III (p<0.05) expression 3 weeks after TAC. LV protein expression of FHL1 (p<0.02) and periostin (p=0.04) were reduced after TAC in AC6-KO mice. The roles of AC6 deletion in cardiac myocytes and fibroblasts were examined in vitro using pharmacological hypertrophy and AC6 knockdown (small interfering ribonucleic acid), which recapitulated in vivo findings. CONCLUSIONS: The deleterious effects of LV pressure overload were reduced in female mice with AC6 deletion. Reductions in FHL1 and periostin expression, direct consequences of reduced AC6 in cardiac myocytes and fibroblasts, appear to be of mechanistic importance for these unanticipated beneficial effects. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Authors: Tong Tang; Mei Hua Gao; N Chin Lai; Amy L Firth; Toshiyuki Takahashi; Tracy Guo; Jason X-J Yuan; David M Roth; H Kirk Hammond Journal: Circulation Date: 2007-12-10 Impact factor: 29.690
Authors: David M Roth; Hamed Bayat; Jeffrey D Drumm; Mei Hua Gao; James S Swaney; Aziz Ander; H Kirk Hammond Journal: Circulation Date: 2002-04-23 Impact factor: 29.690
Authors: N Chin Lai; Tong Tang; Mei Hua Gao; Miho Saito; Toshiyuki Takahashi; David M Roth; H Kirk Hammond Journal: J Am Coll Cardiol Date: 2008-04-15 Impact factor: 24.094
Authors: Toru Oka; Jian Xu; Robert A Kaiser; Jaime Melendez; Michael Hambleton; Michelle A Sargent; Angela Lorts; Eric W Brunskill; Gerald W Dorn; Simon J Conway; Bruce J Aronow; Jeffrey Robbins; Jeffery D Molkentin Journal: Circ Res Date: 2007-06-14 Impact factor: 17.367
Authors: Aziz Guellich; Shumin Gao; Chull Hong; Lin Yan; Thomas E Wagner; Sunil K Dhar; Bijan Ghaleh; Luc Hittinger; Kosaku Iwatsubo; Yoshihiro Ishikawa; Stephen F Vatner; Dorothy E Vatner Journal: Am J Physiol Heart Circ Physiol Date: 2010-06-18 Impact factor: 4.733
Authors: Bo Dai; Wei Huang; Meifeng Xu; Ronald W Millard; Mei Hua Gao; H Kirk Hammond; Donald R Menick; Muhammad Ashraf; Yigang Wang Journal: J Am Coll Cardiol Date: 2011-11-08 Impact factor: 24.094
Authors: Roland Seifert; Gerald H Lushington; Tung-Chung Mou; Andreas Gille; Stephen R Sprang Journal: Trends Pharmacol Sci Date: 2011-11-17 Impact factor: 14.819
Authors: Tong Tang; N Chin Lai; Adam T Wright; Mei Hua Gao; Paul Lee; Tracy Guo; Ruoying Tang; Andrew D McCulloch; H Kirk Hammond Journal: J Mol Cell Cardiol Date: 2013-04-12 Impact factor: 5.000